| Value | ₹94,860 Cr |
|---|
NSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,644.80
- Market cap
- ₹95,530 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.2×Sector 46.1×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Board Meeting Date
Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.
Aurobindo Pharma Other Announcement
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma Business Update
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma Acquisition
Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.
Aurobindo Pharma Acquisition Worth ₹146.4 Cr
Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.
- Value
- ₹146.4 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
- Value
- ₹33.80 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.